Amylin Pharmaceuticals

Nov 05, 09
	NEW STORY
16:15 ET	Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
Nov 02, 09
15:30 ET	Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
Nov 01, 09
18:30 ET	Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Oct 30, 09
20:16 ET	BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
Oct 22, 09
08:00 ET	Amylin Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference
Oct 20, 09
16:05 ET	Amylin Pharmaceuticals Reports Third Quarter Financial Results
Oct 19, 09
16:15 ET	Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
Oct 13, 09
16:05 ET	Amylin Pharmaceuticals to Webcast Third Quarter Results
Sep 24, 09
08:00 ET	Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
Sep 10, 09
16:15 ET	Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
Sep 03, 09
16:15 ET	Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
Aug 24, 09
07:45 ET	Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
Jul 21, 09
16:05 ET	Amylin Pharmaceuticals Reports Second Quarter Financial Results
Jul 20, 09
16:14 ET	Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
Jul 14, 09
16:05 ET	Amylin Pharmaceuticals to Webcast Second Quarter Results
Jul 09, 09
07:45 ET	Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Jul 07, 09
16:05 ET	New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
Jun 17, 09
16:15 ET	Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
Jun 08, 09
18:45 ET	Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
Jun 07, 09
09:15 ET	Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
09:00 ET	Interim Study Results Presented at ADA 2009: Exenatide Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs
Jun 06, 09
18:30 ET	Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar Improvements in Glycemic Control Compared to Rapid-Acting Insulin, With Lower Risk of Hypoglycemia and Without Weight Gain: Data Presented at ADA 2009
Jun 03, 09
16:15 ET	Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
May 29, 09
08:00 ET	Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009
May 12, 09
16:15 ET	Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
May 05, 09
08:00 ET	Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
May 04, 09
16:30 ET	Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
Apr 29, 09
16:43 ET	Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
Apr 23, 09
21:13 ET	Amylin Issues Statement in Response to Carl Icahn
Apr 20, 09
08:00 ET	Psylin Neurosciences Commences Development of Compound for Depression
Apr 16, 09
16:05 ET	Amylin Pharmaceuticals Reports First Quarter Financial Results
Apr 09, 09
16:15 ET	Amylin Pharmaceuticals to Webcast First Quarter Results
Apr 02, 09
20:41 ET	Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Mar 31, 09
08:00 ET	Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
Mar 30, 09
08:09 ET	Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders
Mar 26, 09
08:00 ET	Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Mar 10, 09
16:15 ET	Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
Jan 30, 09
18:57 ET	Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
Jan 29, 09
12:34 ET	Amylin Pharmaceuticals Comments on Shareholder 13-D Filing
Jan 27, 09
16:05 ET	Amylin Pharmaceuticals Reports 2008 Financial Results
Jan 26, 09
16:30 ET	Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
Jan 21, 09
16:15 ET	Amylin Pharmaceuticals to Webcast Year-End Results
Jan 12, 09
13:15 ET	Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
Jan 06, 09
16:58 ET	Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
Nov 13, 08
17:00 ET	Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
Nov 10, 08
17:15 ET	Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
Oct 23, 08
18:54 ET	Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
Oct 21, 08
16:06 ET	Amylin Pharmaceuticals Reports Third Quarter Financial Results
16:05 ET	Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
Oct 15, 08
16:05 ET	Amylin Pharmaceuticals to Webcast Third Quarter Results
Oct 01, 08
16:05 ET	Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
Aug 28, 08
16:05 ET	Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
Aug 26, 08
17:46 ET	Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
Aug 25, 08
17:00 ET	Amylin and Lilly Set Date and Time for Conference Call
Jul 21, 08
16:05 ET	Amylin Pharmaceuticals Reports Second Quarter Financial Results
Jul 15, 08
16:05 ET	Amylin Pharmaceuticals to Webcast Second Quarter Results
Jun 09, 08
19:30 ET	Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
Jun 05, 08
18:30 ET	Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
Jun 02, 08
17:04 ET	Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
May 23, 08
19:00 ET	Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
May 22, 08
16:05 ET	Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
May 12, 08
07:00 ET	Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
May 07, 08
16:05 ET	Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
May 05, 08
17:00 ET	Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
Apr 30, 08
23:30 ET	Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Apr 25, 08
16:05 ET	Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
Apr 21, 08
07:00 ET	Amylin Pharmaceuticals Reports First Quarter Financial Results
Apr 15, 08
16:05 ET	Amylin Pharmaceuticals to Webcast First Quarter Results
Jan 31, 08
16:05 ET	Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Jan 28, 08
16:05 ET	Amylin Pharmaceuticals Reports 2007 Financial Results
Jan 22, 08
16:05 ET	Amylin Pharmaceuticals to Webcast Year-End Results
Jan 07, 08
11:02 ET	SYMLIN Pen-Injector Devices Now Available
Jan 02, 08
16:05 ET	Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
Dec 06, 07
06:00 ET	Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
Nov 30, 07
07:00 ET	Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
Nov 21, 07
07:00 ET	Amylin Pharmaceuticals to Present at Research & Development Day
Nov 15, 07
07:00 ET	Pramlintide and Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss in 24-Week Clinical Obesity Study
Oct 31, 07
06:00 ET	Amylin Pharmaceuticals to Webcast Conference Call
06:00 ET	Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
Oct 30, 07
16:05 ET	Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
Oct 29, 07
16:05 ET	Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
Oct 17, 07
16:05 ET	Amylin Pharmaceuticals Reports Third Quarter Financial Results
Oct 11, 07
16:05 ET	Amylin Pharmaceuticals to Webcast Third Quarter Results
Oct 01, 07
07:00 ET	FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
Sep 14, 07
16:37 ET	Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Aug 31, 07
16:05 ET	Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
Aug 07, 07
16:54 ET	Amylin Resale Registration Statement Declared Effective by SEC
Jul 24, 07
13:42 ET	Amylin Pharmaceuticals Reports Second Quarter Financial Results
Jul 23, 07
16:05 ET	Amylin Pharmaceuticals Reports Second Quarter Financial Results
Jul 16, 07
16:05 ET	Amylin Pharmaceuticals to Webcast Second Quarter Results
Jun 23, 07
11:00 ET	SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes
Jun 19, 07
17:17 ET	Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
Jun 08, 07
16:05 ET	Amylin Pharmaceuticals to Present at Goldman Sachs Healthcare Conference
Jun 06, 07
07:00 ET	Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $75 Million of Convertible Senior Notes
Jun 05, 07
07:00 ET	Amylin Pharmaceuticals, Inc. Announces Pricing of Convertible Senior Notes
Jun 04, 07
07:00 ET	Amylin Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes
May 24, 07
16:05 ET	Amylin Pharmaceuticals to Present at Banc of America Healthcare Conference
May 17, 07
16:05 ET	Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
Apr 26, 07
16:05 ET	Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
Apr 16, 07
06:00 ET	Amylin Pharmaceuticals Reports First Quarter Financial Results
Apr 09, 07
16:05 ET	Amylin Pharmaceuticals to Webcast First Quarter Results
Mar 13, 07
16:05 ET	Amylin Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
Mar 08, 07
16:05 ET	Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
Mar 06, 07
16:29 ET	Amylin Pharmaceuticals Elects Teresa Beck to Board of Directors
Feb 20, 07
16:05 ET	New Storage Instructions Approved for BYETTA(R)
Feb 06, 07
16:05 ET	Amylin Pharmaceuticals Appoints Marcea Bland Lloyd Senior Vice President and General Counsel
Jan 31, 07
16:05 ET	Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Jan 30, 07
16:05 ET	Amylin Pharmaceuticals Announces Appointment of Daniel M. Bradbury as Chief Executive Officer Effective March 1, 2007
16:05 ET	Amylin Pharmaceuticals Reports 2006 Financial Results
Jan 23, 07
16:05 ET	Amylin Pharmaceuticals to Webcast Year-End Results
Jan 03, 07
07:00 ET	FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
07:00 ET	Repeat - FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
Jan 02, 07
16:05 ET	Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
Dec 22, 06
16:05 ET	FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
Nov 24, 06
16:05 ET	Amylin Pharmaceuticals to Present at Piper Jaffray Healthcare Conference
Nov 09, 06
16:05 ET	Amylin Pharmaceuticals to Present at BIOCOM Investor Conference and Credit Suisse Healthcare Conference
Nov 01, 06
16:05 ET	Amylin Pharmaceuticals to Present at Cowen and Company Global Health Care Conference
Oct 24, 06
16:05 ET	Amylin Pharmaceuticals Expands Clinical Program in Obesity
Oct 20, 06
16:05 ET	Amylin Pharmaceuticals to Present at First Annual Research & Development Breakfast
Oct 18, 06
16:05 ET	Amylin Pharmaceuticals Reports Third Quarter Financial Results
Oct 12, 06
16:05 ET	Amylin Pharmaceuticals to Webcast Third Quarter Results
Oct 03, 06
07:15 ET	Amylin Pharmaceuticals Appoints Joe Young Sr. Vice President, Marketing
Sep 22, 06
16:05 ET	Amylin Pharmaceuticals to Present at UBS Warburg Global Life Science Conference
Sep 15, 06
07:05 ET	Amylin Pharmaceuticals to Present at Nordea Novel Anti-Diabetics Seminar, Oppenheimer Diabetes Conference and Merrill Lynch Global Conference
Sep 07, 06
07:05 ET	SYMLIN Improved Diabetes Control in Patients With Type 2 Diabetes on Established Regimens of Basal Insulin
Sep 01, 06
16:05 ET	Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
Aug 24, 06
16:05 ET	Amylin Pharmaceuticals, Inc. Announces Conversion of All Outstanding 2.25% Convertible Senior Notes Due 2008
Jul 31, 06
11:59 ET	Amylin Pharmaceuticals President and COO Daniel Bradbury to Chair San Diego Walk to Cure Diabetes
Jul 24, 06
16:05 ET	Amylin Pharmaceuticals Reports Second Quarter Financial Results
16:05 ET	Amylin Pharmaceuticals, Inc. Announces Details of Redemption of 2.25% Convertible Senior Notes Due June 30, 2008
Jul 21, 06
07:00 ET	Amylin Pharmaceuticals Announces BYETTA Revenue
Jul 17, 06
16:05 ET	Amylin Pharmaceuticals to Webcast Second Quarter Results
Jun 20, 06
16:05 ET	Amylin Pharmaceuticals to Present at William Blair Growth Stock Conference and Piper Jaffray European Healthcare Conference
Jun 10, 06
10:00 ET	Late Breaking Data at ADA 2006 Shows Amylin-Leptin Co-Administration Reduces Body Weight and Body Fat in Animal Studies
Jun 09, 06
16:05 ET	Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
Jun 07, 06
16:15 ET	Amylin Pharmaceuticals Promotes Daniel M. Bradbury to President and Chief Operating Officer
Jun 06, 06
16:05 ET	Amylin Pharmaceuticals Demonstrates Progress Across Diabetes and Obesity Portfolios at ADA 2006
May 25, 06
16:05 ET	Amylin Pharmaceuticals to Present at Friedman Billings Ramsey Growth Conference
May 10, 06
16:05 ET	Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders and Bank of America Health Care Conference
May 01, 06
16:15 ET	Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
Apr 26, 06
16:05 ET	Amylin Pharmaceuticals Reports First Quarter Financial Results
Apr 20, 06
07:00 ET	Amylin Pharmaceuticals Announces BYETTA Revenue
Apr 04, 06
06:30 ET	Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters
Mar 30, 06
06:31 ET	Amylin Pharmaceuticals Announces Public Offering of Common Stock
Mar 28, 06
07:15 ET	Amylin Pharmaceuticals Elects Steven Altman to Board of Directors
Mar 27, 06
06:30 ET	Amylin Pharmaceuticals Announces Public Offering of Common Stock
Mar 24, 06
07:15 ET	Once-Weekly Exenatide LAR Clinical Study in Type 2 Diabetes Initiated
Mar 02, 06
16:53 ET	Amylin Pharmaceuticals to Present at Cowen & Co. Health Care Conference and Lehman Brothers Global Healthcare Conference
Mar 01, 06
16:15 ET	Supplemental New Drug Application for BYETTA Submitted to FDA for Use With TZDs
Feb 22, 06
16:40 ET	Amylin Pharmaceuticals to Present at Citigroup Healthcare Conference
Feb 09, 06
16:07 ET	Pramlintide Obesity Study Results Positive
16:06 ET	Amylin Pharmaceuticals Reports 2005 Financial Results
Feb 02, 06
13:15 ET	Amylin Pharmaceuticals to Webcast Year-End Results
Jan 26, 06
06:30 ET	Amylin Pharmaceuticals Announces BYETTA Revenue
Jan 09, 06
07:15 ET	Amylin Pharmaceuticals Added to the NASDAQ-100 Index
Jan 03, 06
16:18 ET	Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
Dec 29, 05
16:29 ET	Amylin Pharmaceuticals Acquires Facility in Ohio to Manufacture Exenatide LAR
Dec 22, 05
07:15 ET	Amylin Recognized for Biotechnology Leadership and Product Innovation
Dec 21, 05
16:16 ET	Amylin Pharmaceuticals Elects Dr. James Gavin to Board of Directors
Nov 15, 05
16:20 ET	BYETTA Shown to Reduce Blood Sugar Levels When Added to Patients Treated With TZDs
Nov 10, 05
16:15 ET	Amylin Pharmaceuticals to Present at Lehman Brothers Small Cap Conference
Oct 26, 05
16:02 ET	Amylin Pharmaceuticals Reports Third Quarter Financial Results
Oct 20, 05
18:44 ET	Amylin Pharmaceuticals to Webcast Third Quarter Results
Sep 28, 05
16:16 ET	Amylin Pharmaceuticals Elects Karin Eastham to Board of Directors
Sep 22, 05
07:30 ET	Amylin Pharmaceuticals to Present at UBS Global Life Sciences Conference
Sep 19, 05
07:31 ET	Amylin Pharmaceuticals Appoints Roger Marchetti as Senior Vice President of Human Resources and Corporate Services
Sep 09, 05
07:30 ET	Amylin Pharmaceuticals to Present at Bear Stearns Healthcare Conference
Sep 02, 05
16:38 ET	Amylin Pharmaceuticals to Present at Oppenheimer Diabetes Conference, Thomas Weisel Healthcare Tailwinds Conference and Biocentury Newsmakers Conference
Aug 30, 05
07:30 ET	Amylin Pharmaceuticals Announces Public Offering of Common Stock
Aug 22, 05
16:30 ET	Once Weekly Exenatide LAR Well Tolerated and Improved Glucose Control
Aug 04, 05
16:17 ET	Amylin Pharmaceuticals Reports Second Quarter Financial Results
Jul 29, 05
07:30 ET	Amylin Pharmaceuticals to Webcast Second Quarter Results
Jun 23, 05
16:30 ET	Amylin Pharmaceuticals to Present at Bear Stearns Boston Biotech Confab and Friedman Billings Ramsey European Investor Conference
Jun 09, 05
16:43 ET	Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
Jun 06, 05
07:31 ET	Amylin Pharmaceuticals Announces Presentation of 12 Abstracts at the American Diabetes Association Annual Meeting
Jun 03, 05
07:30 ET	Amylin Presents Results From Pramlintide Obesity Program at 14th Annual European Congress on Obesity
May 20, 05
07:15 ET	Amylin Pharmaceuticals to Webcast Annual Meeting of Stockholders and Presentation
May 13, 05
16:15 ET	Amylin Pharmaceuticals to Present at Banc of America Securities' Health Care Conference
May 04, 05
07:32 ET	Amylin Pharmaceuticals Reports First Quarter Financial Results
Apr 29, 05
17:42 ET	Amylin Pharmaceuticals to Webcast First Quarter Results and Morgan Stanley Global Healthcare Unplugged Conference Presentation
Mar 25, 05
16:30 ET	Amylin Pharmaceuticals to Present at Smith Barney Citigroup Healthcare Conference and Lehman Brothers Global Healthcare Conference
Mar 16, 05
16:59 ET	Amylin Pharmaceuticals Announces FDA Approval of SYMLIN(R) for Insulin-Using Type 2 and Type 1 Diabetes
Mar 02, 05
06:01 ET	Amylin Pharmaceuticals Reports 2004 Financial Results
Feb 24, 05
07:15 ET	Amylin Pharmaceuticals to Webcast Year-End Results
Feb 07, 05
07:15 ET	Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Jan 27, 05
06:05 ET	Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters
Jan 21, 05
16:15 ET	Amylin Pharmaceuticals to Present at Piper Jaffray Health Care Conference
06:00 ET	Amylin Pharmaceuticals Announces Public Offering of Common Stock
Jan 18, 05
06:01 ET	Amylin Pharmaceuticals Files Preliminary Prospectus Supplement for Public Offering of Common Stock
Jan 05, 05
07:15 ET	Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
Dec 05, 04
23:00 ET	Amylin Pharmaceuticals Provides Update On Clinical Development Programs
Dec 01, 04
21:01 ET	Amylin Pharmaceuticals to Webcast Corporate Update
Nov 02, 04
07:31 ET	Exenatide LAR Data Support Initiation of Phase 2 Multi-Dose Study in 2005
07:15 ET	Amylin Pharmaceuticals Reports Third Quarter Financial Results
Oct 26, 04
16:31 ET	Amylin Pharmaceuticals to Webcast Third Quarter Results
Sep 22, 04
07:15 ET	Amylin Pharmaceuticals to Present at UBS Global Life Sciences Conference
Sep 20, 04
07:15 ET	Amylin Pharmaceuticals Submits Complete Response to FDA for SYMLIN(R)
Sep 17, 04
16:20 ET	Amylin Pharmaceuticals to Webcast Update on SYMLIN(R) Regulatory Status
Sep 15, 04
16:31 ET	Amylin Pharmaceuticals to Present at Punk Ziegel Diabetes Symposium
Sep 08, 04
16:15 ET	Amylin Pharmaceuticals to Present at Bear Stearns Healthcare Conference
Sep 03, 04
12:20 ET	Amylin Pharmaceuticals to Present at Goldman Sachs Therapeutic Conference
Sep 02, 04
07:15 ET	Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare Conference and BioCentury NewsMakers Conference
Aug 05, 04
07:15 ET	Amylin Pharmaceuticals Reports Second Quarter Financial Results
Jul 30, 04
07:15 ET	Amylin Pharmaceuticals to Webcast Second Quarter Results
Jun 03, 04
07:30 ET	Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
Jun 02, 04
16:15 ET	Amylin Pharmaceuticals to Webcast Data Presented at American Diabetes Association Annual Meeting
May 21, 04
07:30 ET	Amylin Pharmaceuticals Announces Acceptance of 17 Abstracts for Publication at the American Diabetes Association Annual Meeting
May 14, 04
15:31 ET	Amylin Files Resale Registration Statement for Convertible Senior Notes
May 13, 04
07:31 ET	Amylin Pharmaceuticals to Present at Banc of America Securities Healthcare Conference
May 03, 04
16:01 ET	Amylin Pharmaceuticals to Webcast Annual Meeting of Stockholders Presentation
Apr 30, 04
07:31 ET	Amylin Pharmaceuticals To Present At Morgan Stanley Healthcare Conference
Apr 28, 04
07:35 ET	Amylin Pharmaceuticals Reports First Quarter Financial Results
Apr 21, 04
16:15 ET	Amylin Pharmaceuticals to Webcast First Quarter Results
Apr 08, 04
07:31 ET	Amylin Pharmaceuticals to Co-promote Reliant Pharmaceuticals' Family of Cardiovascular Products
Apr 05, 04
18:45 ET	Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $25 Million of Convertible Senior Notes
Mar 31, 04
18:09 ET	Amylin Pharmaceuticals, Inc. Announces Pricing Of Convertible Senior Notes
Mar 30, 04
16:03 ET	Amylin Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes
07:31 ET	Amylin Pharmaceuticals Advances Clinical Pipeline in Diabetes and Obesity
Feb 27, 04
16:44 ET	Amylin Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
Feb 24, 04
07:32 ET	Amylin Pharmaceuticals Reports 2003 Financial Results
Feb 19, 04
07:30 ET	Amylin Pharmaceuticals to Webcast Year-End Results
Feb 12, 04
07:34 ET	Amylin Pharmaceuticals to Present At Roth Capital Partners Growth Stock Conference
Jan 22, 04
17:08 ET	Amylin Pharmaceuticals to Present at U.S. Bancorp Piper Jaffray Healthcare Conference
Jan 12, 04
07:30 ET	Amylin Pharmaceuticals CEO to Provide Corporate Update at JPMorgan Healthcare Conference
Jan 09, 04
16:06 ET	Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
Jan 07, 04
16:45 ET	Amylin Pharmaceuticals Withdraws Swiss Regulatory Application for SYMLIN(R)
Jan 06, 04
07:31 ET	Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
Dec 19, 03
20:53 ET	Amylin Pharmaceuticals Announces Informal Inquiry by the Securities and Exchange Commission
Dec 18, 03
16:15 ET	Amylin and Lilly Announce Achievement of First Exenatide Development Milestones
07:30 ET	Amylin Pharmaceuticals to Webcast Corporate Update Conference Call
Dec 17, 03
18:44 ET	Amylin Pharmaceuticals Receives Second Approvable Letter for SYMLIN(R)
Dec 11, 03
16:30 ET	Amylin Pharmaceuticals Files Shelf Registration Statement
Nov 24, 03
16:30 ET	Amylin Pharmaceuticals to Webcast Corporate Update Conference Call
Nov 04, 03
07:30 ET	Amylin Pharmaceuticals Reports Third Quarter Financial Results
Oct 31, 03
07:31 ET	Amylin Pharmaceuticals Names Michael Hanley As Vice President of Discovery Research
Oct 30, 03
07:31 ET	Amylin Pharmaceuticals to Webcast Third Quarter Company Update Conference Call
Sep 29, 03
07:30 ET	Amylin Resale Registration Statement Declared Effective by SEC
Sep 18, 03
16:15 ET	Amylin Pharmaceuticals to Present at 2003 Morgan Stanley Convertible Conference and UBS Global Life Sciences Conference
Sep 15, 03
16:15 ET	Amylin Pharmaceuticals Elects Joseph P. Sullivan to Board of Directors
Sep 03, 03
16:15 ET	Amylin Pharmaceuticals to Present at Bear Stearns Healthcare Conference And Roth Capital Partners New York Conference
Aug 29, 03
16:21 ET	Amylin Pharmaceuticals to Present at BioCentury Newsmakers Conference And Thomas Weisel Healthcare Conference
Aug 21, 03
16:15 ET	Amylin Pharmaceuticals Announces Plans for 18th Congress of the International Diabetes Federation
Aug 15, 03
16:05 ET	Amylin Files Resale Registration Statement for Convertible Senior Notes
Aug 14, 03
13:20 ET	Amylin Pharmaceuticals to Webcast Second Quarter Company Update Conference Call
13:06 ET	Amylin Pharmaceuticals to Webcast Second Quarter Company Update Conference Call
13:01 ET	/C O R R E C T I O N -- Amylin Pharmaceuticals, Inc./
07:30 ET	Amylin Pharmaceuticals Reports Second Quarter Financial Results
Aug 11, 03
16:30 ET	Amylin Pharmaceuticals to Webcast Second Quarter Company Update Conference Call
Jul 29, 03
07:30 ET	Amylin Pharmaceuticals Reports Encouraging Phase 2 Results From GLP-1 Program In Severe Congestive Heart Failure
Jul 21, 03
07:32 ET	Amylin Pharmaceuticals Repays Johnson & Johnson Loans From Prior SYMLIN(R) Collaboration
Jul 18, 03
07:31 ET	Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $25 Million of Convertible Senior Notes
Jul 14, 03
07:45 ET	Amylin Pharmaceuticals Joins the Russell 1000(R) Index
07:31 ET	Amylin Pharmaceuticals Appoints Joni Harvey As Vice President of Quality Assurance
Jun 18, 03
09:30 ET	Amylin Pharmaceuticals, Inc. Announces Pricing of Convertible Senior Notes
Jun 16, 03
19:12 ET	Amylin Pharmaceuticals Submits New Drug Application Amendment for SYMLIN(R) For the Treatment of Diabetes
17:19 ET	Amylin Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes
Jun 15, 03
19:15 ET	Exenatide Open-Label Study Shows Encouraging Results in People With Type 2 Diabetes
Jun 12, 03
14:09 ET	Amylin Pharmaceuticals to Webcast Investor Update From American Diabetes Association Annual Meeting
Jun 09, 03
16:15 ET	Amylin Pharmaceuticals Names New Chief Executive Officer
Jun 06, 03
07:30 ET	Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
Jun 02, 03
14:19 ET	Exenatide Open-Label Data Accepted for Late-Breaking Presentation at American Diabetes Association Annual Meeting
14:17 ET	Amylin Pharmaceuticals Announces Plans For American Diabetes Association Annual Meeting
May 22, 03
07:30 ET	Amylin Pharmaceuticals Expands Marketing and Sales Management Team
May 19, 03
07:31 ET	Amylin Pharmaceuticals Reports Data From SYMLIN(R) Dose-Titration Study
May 07, 03
07:31 ET	Amylin Pharmaceuticals Reports First Quarter Financial Results
May 02, 03
07:31 ET	Amylin Pharmaceuticals to Webcast First Quarter Company Update Conference Call
Apr 28, 03
07:30 ET	Amylin Pharmaceuticals to Present At Morgan Stanley's Healthcare Unplugged Conference
Mar 31, 03
16:15 ET	Amylin Pharmaceuticals Submits Additional SYMLIN(R) Information to the Swiss Regulatory Authorities
Mar 24, 03
07:30 ET	Amylin Pharmaceuticals to Present At Banc of America Securities Healthcare Conference
Mar 19, 03
07:31 ET	Amylin, Lilly and Alkermes Announce Preliminary Phase 2 Results and Submission Of IND for Exenatide LAR (Sustained Release) Program in Type 2 Diabetes
Mar 13, 03
07:31 ET	Amylin Pharmaceuticals to Present at Roth Capital Partners Growth Stock Conference
Feb 27, 03
07:31 ET	Amylin Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
Feb 20, 03
07:31 ET	Amylin Pharmaceuticals Reports 2002 Financial Results
Feb 13, 03
07:30 ET	Amylin Pharmaceuticals to Webcast Fourth Quarter Company Update Conference Call
Jan 29, 03
16:31 ET	Amylin Pharmaceuticals Completes Acquisition of Rights To Phase 2 GLP-1 Program for Congestive Heart Failure
Jan 22, 03
17:20 ET	Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters
Jan 17, 03
07:30 ET	Amylin Pharmaceuticals Announces Public Offering of Common Stock
Jan 10, 03
16:10 ET	Amylin Pharmaceuticals Files Preliminary Prospectus Supplement for Public Offering of Common Stock
Jan 06, 03
07:31 ET	Amylin and Lilly Announce Completion of Enrollment for Remaining Two Phase 3 Pivotal Trials of AC2993 (Synthetic Exendin-4) in Type 2 Diabetes
Jan 02, 03
16:15 ET	Amylin Pharmaceuticals to Present at JP Morgan H&Q Healthcare Conference
Dec 26, 02
07:30 ET	Amylin Pharmaceuticals to Acquire Rights to Phase 2 GLP-1 Program For Cardiovascular Indication